Antibodies against human BLyS and APRIL attenuate EAE development in marmoset monkeys. - Wikidata - wikimedia - TriplyDB

Antibodies against human BLyS and APRIL attenuate EAE development in marmoset monkeys.

Antibodies against human BLyS and APRIL attenuate EAE development in marmoset monkeys.

http://www.wikidata.org/entity/Q41862447

about

Stage-Specific Role of Interferon-Gamma in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis Role of Tumor Necrosis Factor Superfamily in Neuroinflammation and Autoimmunity A novel nonhuman primate model for influenza transmission The Role of Latently Infected B Cells in CNS Autoimmunity.B Cell in Autoimmune Diseases.Lymphocryptovirus Infection of Nonhuman Primate B Cells Converts Destructive into Productive Processing of the Pathogenic CD8 T Cell Epitope in Myelin Oligodendrocyte Glycoprotein An Evaluation of 20 Years of EU Framework Programme-Funded Immune-Mediated Inflammatory Translational Research in Non-Human Primates.The primate autoimmune encephalomyelitis model; a bridge between mouse and man.A B Cell-Driven Autoimmune Pathway Leading to Pathological Hallmarks of Progressive Multiple Sclerosis in the Marmoset Experimental Autoimmune Encephalomyelitis Model.Monoclonal Antibodies in Preclinical EAE Models of Multiple Sclerosis: A Systematic Review.The different clinical effects of anti-BLyS, anti-APRIL and anti-CD20 antibodies point at a critical pathogenic role of γ-herpesvirus infected B cells in the marmoset EAE model.

P2860

Q26781529-873023A9-E3CE-4125-8CC1-BBECAC00165F Q26800155-00200791-637F-4F81-90E0-2C11DD73ECC9 Q27302967-02FB2875-FD06-45A3-ACED-142ECA9EC3F6 Q36216025-F1551498-30D9-4F56-AD06-123A6C879DE3 Q36954468-B2F94F24-8F9B-4EF5-A161-CF9A809137CF Q37153675-416D4E01-D29A-4199-9056-4104EC4494C0 Q37397401-910E0B82-677F-4238-9659-31724B195375 Q38497590-1E1015A2-6B18-416E-9B55-91CED4F9D7BF Q39458392-889856A2-FFA1-43B8-8550-00310A9781DC Q41660408-8F95BB85-E3A0-4112-9047-920FB08C9DA6 Q43479182-00FD09C5-7304-4630-BF29-08DFC3033CE3

P2860

Antibodies against human BLyS and APRIL attenuate EAE development in marmoset monkeys.

http://www.wikidata.org/entity/Q41862447

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Antibodies against human BLyS and APRIL attenuate EAE development in marmoset monkeys.

@en

type

label

Antibodies against human BLyS and APRIL attenuate EAE development in marmoset monkeys.

@en

prefLabel

Antibodies against human BLyS and APRIL attenuate EAE development in marmoset monkeys.

@en

P1433

Q41862447-53AA0549-174C-4F73-9201-74D83F78586D

P1476

Q41862447-BB2E0294-9352-4847-A614-720F95E86DC2

P2093

Q41862447-0F627DA6-3D8D-4061-9B6B-ED3A163518FB

Q41862447-12F17F2A-D10F-490F-B70D-AD4C721802FB

Q41862447-853FC653-F6DA-48BF-B1C0-2F26DEA6A423

Q41862447-9ADB2B1A-F03A-4428-99AF-5332566DF4E8

Q41862447-A4266384-163E-4B26-8929-6E56D454A882

Q41862447-A70C6406-EFAD-4A18-8F3B-E9AC57AE88C8

Q41862447-F6CC35ED-42CE-493D-89A4-B203B6B14BA5

P2860

Q41862447-04EE67FA-CA99-4C44-A2ED-60DA68C56642

Q41862447-1DDBA7D3-C66B-443F-BA9E-5CE77A442341

Q41862447-23CD7A26-0253-4DF0-BA77-5C3D0CDB9DAB

Q41862447-2BECFD81-1A76-478E-A65A-A733326A1E23

Q41862447-40D68975-1D55-48DE-80E7-D0842843C765

Q41862447-41067031-C587-4525-AFEC-618970515291

Q41862447-486D6E26-789E-4E5E-A8A4-C0EC14CB9904

Q41862447-4BB97497-8728-44C5-A198-DE058A52CD3F

Q41862447-525E181B-697F-40BA-BA6F-DF3E4874B4D9

Q41862447-57B664F5-4C9F-4B09-860A-BDFF718A51D9

P2888

Q41862447-17BD5582-E097-4E7D-9D07-BC0CBBF68929

P304

Q41862447-34CC5B31-E07C-48F2-9BE5-92385EC44715

P31

Q41862447-A8BA9D9F-E18D-4F19-A422-815893811AC8

P356

Q41862447-BABCCC3F-03F9-4693-B459-66F3430E343B

P433

Q41862447-CF712EDA-E904-46A1-82CF-B66167D57BD3

P478

Q41862447-E50B105E-A226-4F85-AD46-9457E435A053

P50

Q41862447-2AED7CAF-BD83-4FE9-878C-8EED65BC2A27

Q41862447-BC8366DE-449D-414B-AD89-6658D0C4D796

P577

Q41862447-C68B7B42-5522-44EE-A6DA-AA82AD758E8E

P5875

Q41862447-E6234D75-CA63-404E-B54D-5F123EE270EE

P698

Q41862447-C638A557-65EC-4F1D-989D-68A652D22993

P932

Q41862447-B154C5A9-8859-4181-B798-46EBB1BCE7A2

P356

S11481-012-9384-X

P1433

Journal of Neuroimmune Pharmacology

P1476

Antibodies against human BLyS and APRIL attenuate EAE development in marmoset monkeys

@en

P2093

Bert A 't Hart

http://www.w3.org/2001/XMLSchema#string

Jon D Laman

http://www.w3.org/2001/XMLSchema#string

Luke Oh

http://www.w3.org/2001/XMLSchema#string

Matt N Devalaraja

http://www.w3.org/2001/XMLSchema#string

Nicole Heijmans

http://www.w3.org/2001/XMLSchema#string

S Anwar Jagessar

http://www.w3.org/2001/XMLSchema#string

Thi-Sau Migone

http://www.w3.org/2001/XMLSchema#string

P2860

BAFF, APRIL, TWE-PRIL: Who's who?

Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study

The immunopathology of multiple sclerosis: an overview

Reactivation by exon shuffling of a conserved HLA-DR3-like pseudogene segment in a New World primate species.

Discrepant effects of human interferon-gamma on clinical and immunological disease parameters in a novel marmoset model for multiple sclerosis.

Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate.

Space, selection, and surveillance: setting boundaries with BLyS.

B-cell depletion and repopulation in autoimmune diseases.

Novel therapeutic strategies for multiple sclerosis--a multifaceted adversary.

Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project.

P2888

s11481-012-9384-x

P304

557-570

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11481-012-9384-X

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-06-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230631440

http://www.w3.org/2001/XMLSchema#string

P698

22870852

http://www.w3.org/2001/XMLSchema#string

P932

3419352

http://www.w3.org/2001/XMLSchema#string